2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Características clínicas de COVID-19 en trabajadores sanitarios de tres hospitales de Madrid durante la primera ola de la pandemia Translated title: Clinical characteristics of COVID-19 in healthcare workers from three hospitals from Madrid during the first wave of the pandèmic

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen Introducción: El objetivo Disminuir el área de incertidumbre con la comprensión de la sintomatología y la caracterización clínica dentro del entorno hospitalario. Método: Este es un estudio descriptivo comparativo, donde se revisaron y compararon las manifestaciones clínicas de 255 trabajadores sanitarios con COVID-19 durante la primera ola (marzo-abril 2020). De acuerdo a las características se hizo el análisis de los resultados utilizando las pruebas chi cuadrado, U de Mann-Whitney/w de Wilcoxon y las medidas de tendencia central. Resultados: La anosmia y la ageusia tuvieron un vínculo estadísticamente significativo con la obtención de un resultado positivo en la PCR: Anosmia p=0,001; Ageusia: p=0,00; fiebre (p=0,01) y la odinofagia (p=0,03). La tos 75,56%, mialgias 68,11%, cefalea 43,53%, anosmia 37,25%, fiebre 34,12 % y ageusia 31,76% sobresalieron dentro de los síntomas. La positividad de la PCR tras el inicio de los síntomas estuvo entre 1.5 a 4 días. Conclusiones: Es primordial utilizar un enfoque que al menos incluya la fiebre, anosmia o ageusia al establecer aislamiento y la determinación de pruebas diagnósticas. La caracterización clínica es fundamental para poder establecer estrategias sanitarias efectivas. Nuevas variantes del SARS CoV-2 podrían alterar la efectividad de estas estrategias.

          Translated abstract

          Abstract Introduction: Le objective is reduce the area of uncertainty with the understanding of the symptoms and the clinical characterization within the hospital environment. Method: This is a comparative descriptive study, where the clinical manifestations of 255 healthcare workers with COVID-19 during the first wave (March-April 2020) were reviewed and compared. According to the characteristics, the analysis of the results was performed using the chi-square tests, Mann-Whitney U / w. Wilcoxon and measures of central tendency. Results: Anosmia and ageusia had a statistically significant relationship with obtaining a positive result in the PCR: Anosmia p = 0.001; Ageusia: p = 0.00; fever (p = 0.01) and odynophagia (p = 0.03). Cough 75.56%, myalgia 68.11%, headache 43.53%, anosmia 37.25%, fever 34.12% and ageusia 31.76% stood out among the symptoms. The positivity of the PCR after the onset of symptoms was between 1.5 to 4 days. Conclusions: It is essential to use an approach that at least includes fever, anosmia or ageusia when establishing isolation and determining diagnostic tests. Clinical characterization is essential to be able to establish effective health strategies. New variants of SARS CoV-2 could alter the effectiveness of these strategies.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical Characteristics of Coronavirus Disease 2019 in China

          Abstract Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients. Methods We extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death. Results The median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission. Conclusions During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            A pneumonia outbreak associated with a new coronavirus of probable bat origin

            Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats 1–4 . Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans 5–7 . Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

              Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
                Bookmark

                Author and article information

                Journal
                mesetra
                Medicina y Seguridad del Trabajo
                Med. segur. trab.
                Escuela Nacional de Medicina del Trabajo. Instituto de Salud Carlos III (Madrid, Madrid, Spain )
                0465-546X
                1989-7790
                March 2021
                : 67
                : 262
                : 11-23
                Affiliations
                [2] Madrid orgnameHospitales Universitarios Rey Juan Carlos, Infanta Elena y General de Villalba orgdiv1Servicio de Prevención Mancomunado España
                [3] Madrid orgnameHospitales Universitarios Rey Juan Carlos, Infanta Elena y General de Villalba orgdiv1Servicio de Prevención Mancomunado España
                [1] Madrid orgnameHospitales Universitarios Rey Juan Carlos, Infanta Elena y General de Villalba orgdiv1Servicio de Prevención Mancomunado España
                Article
                S0465-546X2021000100011 S0465-546X(21)06726200011
                10.4321/s0465-546x2021000100002
                ceed4a8d-bb0b-4e73-abc8-3bd9f838beed

                This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

                History
                : 28 March 2021
                : 20 February 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 34, Pages: 13
                Product

                SciELO Spain

                Categories
                Artículo Especial

                SARS-CoV-2,COVID-19,SARS-CoV-2 PCR clinical characteristics,healthcare workers,trabajadores de la salud,PCR de SARS-CoV-2 características clínicas

                Comments

                Comment on this article